PCOS and Biological Age: How Polycystic Ovary Syndrome Drives Long-Term Inflammation

Polycystic ovary syndrome (PCOS) is associated with a measurably higher biological age, driven by the chronic, low-grade inflammation and insulin resistance that characterize the condition. Women with PCOS frequently show a biological age 10 or more years above their chronological age, even when standard blood panels appear unremarkable. This inflammatory burden can be tracked directly through IgG glycosylation (the pattern of complex sugars attached to Immunoglobulin G antibodies), offering a window into how PCOS affects long-term immune aging that standard panels miss.

For a broader understanding of how hormonal transitions affect biological age, see our definitive guide to Menopause, HRT & Biological Age: The Definitive Guide to Tracking Hormonal Aging.

Why does PCOS accelerate biological aging?

PCOS is a hormonal condition marked by irregular or absent periods, and often accompanied by weight gain (particularly around the abdomen), excess hair growth, and acne — physical signs that reflect an underlying hormonal imbalance. Beneath these symptoms, PCOS accelerates biological aging primarily through two overlapping mechanisms: chronic low-grade inflammation and insulin resistance, both of which shift the immune system toward a pro-inflammatory state. Glycans (the complex sugar molecules that coat IgG antibodies and regulate whether those antibodies promote or suppress inflammation) become shorter and more pro-inflammatory as this inflammatory burden accumulates. The result is a measurable shift in the glycome: anti-inflammatory glycan indexes decline, pro-inflammatory ones rise, and biological age climbs.

"Inflammation is a process where you destroy infected tissue — immune cells come in, fight the enemy, there is damage, and then this damage is repaired. But the low-grade chronic inflammation that happens all around the body all the time consumes huge amounts of energy and leaves microscopic scars of damage, which promotes more inflammation. It is a vicious circle that leads to aging."

— Prof. Gordan Lauc, Co-Founder & CSO, GlycanAge

In women with PCOS, this cycle is compounded by insulin resistance, which independently drives pro-inflammatory glycan production and further elevates biological age.

How does GlycanAge detect the inflammatory signature of PCOS?

GlycanAge detects PCOS-related inflammation through a specific pattern in the glycan indexes: all five glycan indexes, including the three primary indexes that determine biological age, cluster around the 50th percentile, yet biological age sits 10 or more years above chronological age. This pattern of unremarkable index distribution alongside significantly elevated biological age is a recognisable clinical signature in women with PCOS and underlying insulin resistance.

Standard PCOS workups typically test blood sugar, cholesterol, and hormone levels (testosterone, LH, FSH), which are markers that assess metabolic and hormonal status at the moment of testing. What they don't capture is the cumulative inflammatory burden driving biological aging over time. IgG antibodies have a half-life of approximately six weeks, meaning the glycan composition of your antibody pool reflects your inflammatory state over the preceding three months, not a single moment in time. This makes GlycanAge a useful addition alongside standard PCOS testing: it can flag sustained, low-grade inflammation earlier, even when glucose, lipid, and hormone panels appear within normal range.

Does PCOS cause the same inflammatory aging as menopause?

PCOS and menopause drive biological aging through related but distinct mechanisms, and both are measurable through IgG glycosylation. In perimenopause, glycans shift rapidly from immunosuppressive to pro-inflammatory as estrogen declines. Women can biologically age by more than a decade in glycan years within only a few months of this transition. In PCOS, the driver is not primarily estrogen deficiency but chronic inflammation and insulin resistance, which produce a similarly elevated biological age through a different hormonal pathway.

What the two conditions share is the direction of change: both push the glycome toward shorter, pro-inflammatory glycan structures and away from the longer, anti-inflammatory forms associated with immune resilience. Women with PCOS who later enter perimenopause may therefore face a compounded inflammatory burden, arriving at the menopausal transition with a biological age already significantly elevated above their chronological age.

Can treating PCOS lower biological age?

Targeted interventions for PCOS, such as addressing insulin resistance, inflammation, and hormonal imbalance, are associated with measurable reductions in biological age through the glycan indexes. Weight loss generally produces positive changes in the glycome: biological age decreases, anti-inflammatory glycans increase, and pro-inflammatory load falls. Note that extreme or rapid weight loss can temporarily elevate GlycanAge as inflammatory molecules stored in adipose tissue enter circulation. This is a transient effect that resolves as fat reduction stabilises. Metformin, commonly used to address insulin resistance in PCOS, has shown potential beneficial effects on the IgG glycome in individuals with metabolic dysfunction. GlycanAge's preliminary data suggests these effects may be meaningful for women with active insulin resistance, though the evidence base is still developing.

Because IgG antibodies turn over approximately every three months, any intervention needs at least that long before a meaningful change in GlycanAge is detectable. Retesting at 3–4 months after initiating a pharmacological protocol such as metformin, or at 6 months or more for lifestyle-based programmes, gives a reliable read on whether the intervention is reducing the inflammatory burden at a biological level. This is the practical value of GlycanAge for women managing PCOS: it converts subjective symptom tracking into an objective, measurable signal.

"What I love about the GlycanAge test is that you can see changes within three months. The changes occur quickly — you can see them, monitor what you're doing, and alter your therapy if you need to."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical, New York

Does an irregular menstrual cycle affect GlycanAge results?

Irregular menstrual cycles are independently associated with a higher GlycanAge score, separate from the effect of PCOS itself. In a study of 70 healthy premenopausal women with regular cycles, average variation in glycan indexes across the menstrual cycle was only up to 1.1%, not enough to affect the overall GlycanAge score. Women with irregular cycles or conditions like PCOS, characterized by hormonal imbalance and increased inflammation, show a consistently elevated GlycanAge score rather than the small cyclic fluctuation seen in regular cycles.

This distinction matters clinically: a single GlycanAge result in a woman with PCOS reflects a sustained inflammatory state, not a transient hormonal fluctuation. It is a stable signal, not noise.

When should a woman with PCOS consider testing her biological age?

The right time to test is before initiating a new intervention, whether that is a dietary change, a weight loss protocol, metformin, or any other targeted therapy, so that a meaningful baseline exists. A follow-up test at three to six months then shows whether the intervention has shifted the glycome in the right direction. For women with PCOS approaching perimenopause, establishing a biological age baseline is particularly valuable: it captures the inflammatory burden already present before the additional pro-inflammatory shift of hormonal transition begins.

GlycanAge is not a diagnostic tool for PCOS. It measures the inflammatory biology associated with the condition and tracks whether interventions are working at the immune level. This information complements, rather than replaces, clinical assessment.

If you are managing PCOS and want to measure whether your current protocol is reducing your inflammatory age, a GlycanAge test gives you an objective biological baseline and a 1:1 result interpretation call with a longevity specialist who can walk you through your glycan indexes and what they mean for your health strategy.

Order Your GlycanAge Test

External sources

• https://www.sciencedirect.com/science/article/pii/S2095809923002436?via%3Dihub — Jurić J, Peng Y, Song M, Vučković F, Šimunović J, Trbojević-Akmačić I, Wang W, Liu L, Gao R, Wang Z, Chu Y, Pezer M, Wang W, Lauc G. Periodic Changes in the N-Glycosylation of Immunoglobulin G During the Menstrual Cycle. Engineering. 2023;26:108–118.

• https://www.cell.com/iscience/fulltext/S2589-0042(22)00167-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004222001675%3Fshowall%3Dtrue — Deriš H, Kifer D, Cindrić A, Petrović T, Cvetko A, Trbojević-Akmačić I, Kolčić I, Polašek O, Newson L, Spector TD, Menni C, Lauc G. Immunoglobulin G glycome composition in transition from premenopause to postmenopause. iScience. 2022;25(3):103897.

• https://www.nature.com/articles/s41574-018-0059-4 — Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 2018;14(10):576–590.